132 related articles for article (PubMed ID: 38367816)
21. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
22. The genetics of vascular birthmarks.
Mahajan P; Bergstrom KL; Phung TL; Metry DW
Clin Dermatol; 2022; 40(4):313-321. PubMed ID: 35181412
[TBL] [Abstract][Full Text] [Related]
23. Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
Tsujioka Y; Nozaki T; Niimi Y; Starkey J; Hasegawa D; Kondo M; Enokizono M; Makidono A; Kono T; Jinzaki M
Clin Imaging; 2022 Sep; 89():162-173. PubMed ID: 35849880
[TBL] [Abstract][Full Text] [Related]
24. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity.
Sterba M; Pokorna P; Faberova R; Pinkova B; Skotakova J; Seehofnerova A; Blatny J; Janigova L; Koskova O; Palova H; Mahdal M; Pazourek L; Jabandziev P; Slaby O; Mudry P; Sterba J
Sci Rep; 2023 Jun; 13(1):10499. PubMed ID: 37380669
[TBL] [Abstract][Full Text] [Related]
25. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.
Hori Y; Hirose K; Aramaki-Hattori N; Suzuki S; Nakayama R; Inoue M; Matsui T; Kohara M; Toyosawa S; Morii E
Diagn Pathol; 2020 Jul; 15(1):98. PubMed ID: 32711543
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
Guan R; Kang Z; Li L; Yan X; Gao T
PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
[TBL] [Abstract][Full Text] [Related]
28. Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.
Chen H; Gao W; Liu H; Sun B; Hua C; Lin X
Ann Plast Surg; 2023 May; 90(5S Suppl 2):S209-S215. PubMed ID: 36729078
[TBL] [Abstract][Full Text] [Related]
29. A Patient-Derived Xenograft Model for Venous Malformation.
Schrenk S; Goines J; Boscolo E
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867
[TBL] [Abstract][Full Text] [Related]
30. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.
Mussa A; Leoni C; Iacoviello M; Carli D; Ranieri C; Pantaleo A; Buonuomo PS; Bagnulo R; Ferrero GB; Bartuli A; Melis D; Maitz S; Loconte DC; Turchiano A; Piglionica M; De Luisi A; Susca FC; Bukvic N; Forleo C; Selicorni A; Zampino G; Onesimo R; Cappuccio G; Garavelli L; Novelli C; Memo L; Morando C; Della Monica M; Accadia M; Capurso M; Piscopo C; Cereda A; Di Giacomo MC; Saletti V; Spinelli AM; Lastella P; Tenconi R; Dvorakova V; Irvine AD; Resta N
J Med Genet; 2023 Feb; 60(2):163-173. PubMed ID: 35256403
[TBL] [Abstract][Full Text] [Related]
31. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive molecular and clinicopathological analysis of vascular malformations: A study of 319 cases.
Ten Broek RW; Eijkelenboom A; van der Vleuten CJM; Kamping EJ; Kets M; Verhoeven BH; Grünberg K; Schultze Kool LJ; Tops BBJ; Ligtenberg MJL; Flucke U
Genes Chromosomes Cancer; 2019 Aug; 58(8):541-550. PubMed ID: 30677207
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutations in vascular malformations.
Castillo SD; Baselga E; Graupera M
Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
35. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
36. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
37. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation.
Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G
Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
39. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
40. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
